Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Brain scans and imaging

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objective Recommendations for the diagnosis of preclinical Alzheimer disease (AD) have been formulated by a workgroup of the National Institute on Aging and Alzheimer's Association. Three stages of preclinical AD were described. Stage 1 is characterized by abnormal levels of β-amyloid. Stage 2 represents abnormal levels of β-amyloid and evidence of brain neurodegeneration. Stage 3 includes the features of stage 2 plus subtle cognitive changes. Stage 0, not explicitly defined in the criteria, represents subjects with normal biomarkers and normal cognition. The ability of the recommended criteria to predict progression to cognitive impairment is the crux of their validity. Methods Using previously developed operational definitions of the 3 stages of preclinical AD, we examined the outcomes of subjects from the Mayo Clinic Study of Aging diagnosed as cognitively normal who underwent brain MRI or [(18)F]fluorodeoxyglucose and Pittsburgh compound B PET, had global cognitive test scores, and were followed for at least 1 year. Results Of the 296 initially normal subjects, 31 (10%) progressed to a diagnosis of mild cognitive impairment (MCI) or dementia (27 amnestic MCI, 2 nonamnestic MCI, and 2 non-AD dementias) within 1 year. The proportion of subjects who progressed to MCI or dementia increased with advancing stage (stage 0, 5%; stage 1, 11%; stage 2, 21%; stage 3, 43%; test for trend, p Conclusions Despite the short follow-up period, our operationalization of the new preclinical AD recommendations confirmed that advancing preclinical stage led to higher proportions of subjects who progressed to MCI or dementia.

What this study adds

Evidence grade: Low

In 296 cognitively normal people from the Mayo Clinic Study of Aging, the share diagnosed with mild cognitive impairment or dementia over about a year rose with each preclinical Alzheimer stage: 5% at stage 0, 11% at stage 1, 21% at stage 2 and 43% at stage 3. Most of the 31 people who progressed developed mild cognitive impairment (2 developed non-Alzheimer dementias), and the authors note the follow-up was short.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V., et al. (2012). Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0b013e3182563bbe

Vancouver

Knopman DS, Jack CR, Wiste HJ, Weigand SD, Vemuri P, Lowe V, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012. doi:10.1212/wnl.0b013e3182563bbe. PMID: 22551733.

BibTeX

@article{knopman2012-22551733,
  author  = {Knopman, D. S. and Jack, C. R. and Wiste, H. J. and Weigand, S. D. and Vemuri, P. and Lowe, V. and Kantarci, K. and Gunter, J. L. and others},
  title   = {{Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease}},
  journal = {Neurology},
  year    = {2012},
  doi     = {10.1212/wnl.0b013e3182563bbe},
  pmid    = {22551733},
  url     = {https://doi.org/10.1212/wnl.0b013e3182563bbe}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In 296 cognitively normal people from the Mayo Clinic Study of Aging, the share diagnosed with mild cognitive impairment or dementia over about a year rose with each preclinical Alzheimer stage: 5% at stage 0, 11% at stage 1, 21% at stage 2 and 43% at stage 3. Most of the 31 people who progressed developed mild cognitive impairment (2 developed non-Alzheimer dementias), and the authors note the follow-up was short. The result supports the staging for grading risk, but it does not predict outcomes for individuals and tested no treatment or prevention.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 2 of 4; Senior author's track record 1 of 4; Institution's track record 2 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 49 of 100.49 of 100 points earned51 not earned

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2012 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 242 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 15.1 citations a year over 16 year(s) since 2012
Impact for its field and year 5 / 6 Cited 20.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 42 other studies in this library
Still being cited 2 / 4 Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Ronald C. Petersen: h-index 18 (OpenAlex, whole career)
Institution's track record 2 / 3 Mayo Clinic: institution h-index 1,606 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 22551733)
Free to read 0 / 2 Behind a paywall — scores zero
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.

Later studies that cite this one

42 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Brain scans and imaging from nearby years

Also in Brain scans and imaging

136 studies in the library are filed under Brain scans and imaging with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Brain scans and imaging hub.

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →